Edition:
India

Profile: Precision BioSciences Inc (DTIL.OQ)

DTIL.OQ on NASDAQ Stock Exchange Global Select Market

9.66USD
20 Sep 2019
Change (% chg)

$-0.39 (-3.88%)
Prev Close
$10.05
Open
$10.08
Day's High
$10.10
Day's Low
$9.60
Volume
58,947
Avg. Vol
53,371
52-wk High
$19.00
52-wk Low
$7.80

Precision BioSciences, Inc., incorporated on June 26, 2006, is a genome editing company. The Company is engaged in providing genome engineering technology. The Company’s ARCUS genome editing technology enables the production of specific nucleases that can insert, remove and modify deoxyribonucleic acid (DNA) at any location in a genome. The Company is also engaged in developing genome editing-based product leads for human therapeutic, agricultural and biologics manufacturing applications. The Company’s four product candidates in its CAR T cell development pipeline are PBCAR0191, PBCAR20A, PBCAR269A and PBCAR371A. The Company’s ARCUS platform designed to treat human diseases and create healthy and sustainable food and agricultural solutions. It also developing product candidates in three areas to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food.

PBCAR0191 is an allogeneic anti-CD19 CAR T cell product candidate for the treatment of R/R B-Cell precursor ALL and R/R NHL. CD19 is a protein that is expressed on the surface of B cells. It is a well-validated target for CAR T cell therapy. The Company is in the process of Phase I/IIa clinical trial in patients with R/R B-Cell precursor ALL and R/R NHL. PBCAR20A is an allogeneic anti-CD20 CAR T cell product candidate for the treatment of Chronic Lymphocytic Leukemia, or CLL, and Small Lymphocytic Lymphoma, or SLL. Like CD19, CD20 is a protein expressed on the surface of B cells. It is an established target for cancer treatment and several CD20-targeted therapies, such as the monoclonal antibody Rituxan.

PBCAR269A is an allogeneic anti-BCMA CAR T cell product candidate for the treatment of multiple myeloma. BCMA is a protein that is expressed on the surface of mature B cells called plasma cells that are responsible for the disease and is a validated CAR T cell target. PBCAR371A is an allogeneic anti-CLL-1 CAR T cell product candidate for the treatment of acute myeloid leukemia or AML. CLL-1 is a protein that is expressed on myeloid cells, including many AML cancer cells.

Company Address

Precision BioSciences Inc

302 E Pettigrew St Ste A100
DURHAM   NC   27701-2393
P: +1919.3145512
F: +1480.3935553

Company Web Links